Molecular Biomarkers & Theranostics
Leader : David TAIEB (AMU/APHM, CERIMED, CRCM)
Once methodological developments, transferred, validated, and applied on (pre)clinical platforms, they will be implemented to scientifically address molecular biomarker/theranostic issues on (pre)clinical models, relying on personalized medicine concept. Besides multimodal imaging, interventional procedures are especially integrated to obtain biopsies of targeted lesions for molecular correlation/validation, and to deliver imaging/therapeutic agents by IGT. On the whole, diagnostic/therapeutic interactions will be developed to select patients, as well as to guide, predict, and evaluate treatments, according to the molecular signature of the disease and of the lesions; but also to treat directly with vector-based approaches using internal/metabolic radiation therapy, and/or interventional procedures to deliver therapeutic agents (IGT), and finally improve healthcare. Several theranostics are proposed by DHU-Imaging partners involved in Neurosciences (APHM, INT) and Oncology (APHM, CRO2, CRCM, VRCM), in close relationship with the two APHM Comprehensive Cancer of SIRIC-Marseille for Brain Tumor and Pancreatic Tumor, and the APHM-IPC biobanks. Our projects will be focused on neuropsychiatric disorders, brain tumors and neuroendocrine tumors (including pancreas). Prostate cancer (PC) has been included in this latter tumor phenotype since PC exhibits structural and functional neuroendocrine features that can be targeted by molecular imaging (i.e. neuropeptides receptors), and since its neuroendocrine component is involved in resistance to androgen castration. Thus, in the whole, DHU-Imaging essentially considers tumoral and non-tumoral diseases of - or derived from - the nervous system, including by extension the neuroendocrine tumors.